As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib
Table 1
Baseline demographics and clinical characteristics of the patients (N = 235).
Characteristics
Number (%)/mean ± S.D./median [IQR]
Age (year)
51.3 ± 12.0
Gender (men/women)
200 (85.1)/35 (14.9)
Etiology (HBV/HCV/other)
201 (85.5)/9 (3.8)/25 (10.6)
Child-pugh (A/B)
226 (96.2)/9 (3.8)
ECOG (0/1)
121 (51.5)/114 (48.5)
BCLC (A/B/C)
13 (5.5)/70 (29.8)/152 (64.7)
Previous treatments (yes/no)
20 (8.5)/215 (91.5)
Tumor burden
Tumor size (cm)
8.5 [6.0–12.3]
No. of HCC nodules
1 [1-2]
PVTT (absent/present)
166 (70.6)/69 (29.4)
EHS (absent/present)
173 (73.6)/62 (26.4)
AFP (ng/mL)
414.5 [12.6–9380.5]
Baseline laboratory values
Leukocyte (×10E9/L)
5.8 ± 2.7
Hemoglobin (g/L)
137.3 ± 20.5
Platelets (×10E9/L)
144.3 ± 78.6
INR
1.11 ± 0.13
ALT (U/L)
46.0 ± 31.6
AST (U/L)
61.0 ± 43.9
Albumin (g/L)
39.3 ± 5.2
Total bilirubin (μmol/L)
17.5 ± 8.8
Urea nitrogen (mmol/L)
5.0 ± 1.6
Serum creatinine (μmol/L)
83.6 ± 16.6
Abbreviations: S.D., standard deviation; IQR, inter quartile range; HBV, hepatitis B virus; HCV, hepatitis C virus; ECOG, Eastern cooperative oncology group; BCLC, Barcelona clinic liver cancer; PVTT, portal vein tumor thrombus; EHS, extrahepatic spreading; AFP, alpha-fetoprotein; INR, International normalized ratio; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase.
